MCID: ACT135
MIFTS: 58

Acute Graft Versus Host Disease

Categories: Blood diseases, Bone diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Acute Graft Versus Host Disease

MalaCards integrated aliases for Acute Graft Versus Host Disease:

Name: Acute Graft Versus Host Disease 54 60
Acute Graft-Versus-Host Disease 56
Acute Gvh Disease 74
Acute Gvhd 54

Classifications:

Orphanet: 60  
Rare immunological diseases


External Ids:

ICD10 via Orphanet 35 T86.0
UMLS via Orphanet 75 C0856825
Orphanet 60 ORPHA99920
UMLS 74 C0856825

Summaries for Acute Graft Versus Host Disease

MalaCards based summary : Acute Graft Versus Host Disease, also known as acute graft-versus-host disease, is related to hematopoietic stem cell transplantation and graft-versus-host disease. An important gene associated with Acute Graft Versus Host Disease is ARHGAP45 (Rho GTPase Activating Protein 45), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Mycophenolic acid and Basiliximab have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone and bone marrow, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Related Diseases for Acute Graft Versus Host Disease

Diseases in the Graft-Versus-Host Disease family:

Acute Graft Versus Host Disease Chronic Graft Versus Host Disease

Diseases related to Acute Graft Versus Host Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 306)
# Related Disease Score Top Affiliating Genes
1 hematopoietic stem cell transplantation 31.2 ARHGAP45 IFNG IL10 IL2 TNF
2 graft-versus-host disease 31.1 ARHGAP45 FASLG GZMB IFNG IL10 IL2
3 chronic graft versus host disease 30.5 IFNG IL10 IL2RA TNF
4 aspergillosis 30.2 IFNG IL10 IL4 TNF
5 bronchiolitis 30.0 IFNG IL10 IL4 TNF
6 aplastic anemia 29.9 FASLG IFNG IL2 IL4 TNF
7 lymphopenia 29.7 FASLG IFNG IL2 IL2RA
8 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 29.7 IFNG IL10 IL2 IL2RA IL4
9 bronchiolitis obliterans 29.7 GZMB IFNG IL10 TNF
10 erythema multiforme 29.6 FASLG GZMB IFNG IL2 TNF
11 lichen planus 29.6 GZMB IFNG IL4 TNF
12 mouth disease 29.5 IFNG IL10 TNF
13 severe cutaneous adverse reaction 29.5 FASLG GZMB TNF
14 colitis 29.4 IFNG IL10 IL2 IL4 NOD2 TNF
15 inflammatory bowel disease 29.1 IFNG IL10 IL18 IL2 IL4 NOD2
16 leukemia 10.7
17 tuberculoid leprosy 10.5 IFNG IL10
18 fungal meningitis 10.5 IFNG IL10
19 sporotrichosis 10.5 IFNG IL10
20 pericardial tuberculosis 10.5 IFNG IL10
21 retinitis pigmentosa 44 10.5 IL10 IL2
22 variola major 10.5 IFNG IL2
23 berylliosis 10.5 IFNG IL2
24 cow milk allergy 10.5 IL10 TNF
25 choroiditis 10.5 IL10 TNF
26 trachoma 10.5 IL10 TNF
27 trichuriasis 10.5 IL10 TNF
28 transient hypogammaglobulinemia 10.5 IL10 TNF
29 mucocutaneous leishmaniasis 10.5 IL10 TNF
30 trichosporonosis 10.5 IFNG TNF
31 microscopic colitis 10.5 IFNG TNF
32 idiopathic achalasia 10.5 IL10 TNF
33 fixed drug eruption 10.5 IFNG IL2
34 multifocal choroiditis 10.5 IL10 TNF
35 miliary tuberculosis 10.5 IFNG TNF
36 autoimmune myocarditis 10.5 IFNG TNF
37 staphylococcal toxic shock syndrome 10.5 IFNG TNF
38 chronic beryllium disease 10.5 IFNG TNF
39 farmer's lung 10.5 IL2 TNF
40 retinitis pigmentosa 22 10.4 IL10 IL4
41 apple allergy 10.4 IL10 IL4
42 beta-lactam allergy 10.4 IL10 IL4
43 eosinophilic meningitis 10.4 IL10 IL4
44 streptococcal toxic-shock syndrome 10.4 IL2 TNF
45 b-cell growth factor 10.4 IFNG IL4
46 cervicitis 10.4 IL2 IL2RA
47 penicillin allergy 10.4 IFNG IL4
48 crustacean allergy 10.4 IFNG IL4
49 autoimmune vasculitis 10.4 IL2 IL4
50 angiostrongyliasis 10.4 IL2 IL4

Graphical network of the top 20 diseases related to Acute Graft Versus Host Disease:



Diseases related to Acute Graft Versus Host Disease

Symptoms & Phenotypes for Acute Graft Versus Host Disease

GenomeRNAi Phenotypes related to Acute Graft Versus Host Disease according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.78 GZMB IL10 IL18 IL2 IL2RA NOD2
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.78 GZMB IL10 IL18 IL2 IL2RA NOD2

MGI Mouse Phenotypes related to Acute Graft Versus Host Disease:

47 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.22 FASLG IFNG IL10 IL18 IL2 IL4
2 digestive/alimentary MP:0005381 10.21 FASLG IFNG IL10 IL18 IL2 IL2RA
3 hematopoietic system MP:0005397 10.2 FASLG IFNG IL10 IL18 IL2 IL2RA
4 growth/size/body region MP:0005378 10.18 IFNG IL10 IL18 IL2 IL2RA IL4
5 homeostasis/metabolism MP:0005376 10.17 FASLG IFNG IL10 IL18 IL2 IL2RA
6 immune system MP:0005387 10.14 FASLG IFNG IL10 IL18 IL2 IL2RA
7 endocrine/exocrine gland MP:0005379 10.04 FASLG IFNG IL10 IL2 IL2RA IL4
8 mortality/aging MP:0010768 10 FASLG IFNG IL10 IL18 IL2 IL2RA
9 integument MP:0010771 9.91 FASLG IFNG IL10 IL18 IL4 TNF
10 liver/biliary system MP:0005370 9.87 FASLG IFNG IL10 IL2 IL4 TNF
11 no phenotypic analysis MP:0003012 9.63 IFNG IL10 IL2 IL4 MYH9 TNF
12 respiratory system MP:0005388 9.56 FASLG IFNG IL10 IL2 IL2RA IL4
13 vision/eye MP:0005391 9.28 FASLG IFNG IL10 IL18 IL2 IL2RA

Drugs & Therapeutics for Acute Graft Versus Host Disease

Drugs for Acute Graft Versus Host Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 405)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 24280-93-1 446541
2
Basiliximab Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 152923-56-3, 179045-86-4
3
Methotrexate Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 1959-05-2, 59-05-2 126941
4
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
5
leucovorin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 58-05-9 6006 143
6
Lomustine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 13010-47-4 3950
7
Cyclophosphamide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 6055-19-2, 50-18-0 2907
8
Busulfan Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 55-98-1 2478
9
Cytarabine Approved, Experimental, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 147-94-4, 65-46-3 6253
10
Infliximab Approved Phase 4,Phase 2,Phase 1 170277-31-3
11
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 104987-11-3 445643 439492 6473866
12
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 135968-09-1
13
Sargramostim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 123774-72-1, 83869-56-1
14
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 75607-67-9, 21679-14-1 30751
15
Vidarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 24356-66-9 21704 32326
16
Foscarnet Approved Phase 4,Not Applicable 63585-09-1, 4428-95-9 3415
17
Ganciclovir Approved, Investigational Phase 4,Not Applicable 82410-32-0 3454
18
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
19
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 59-30-3 6037
20
Lactitol Investigational Phase 4,Phase 2 585-86-4, 585-88-6 493591
21
Semustine Experimental, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 13909-09-6
22
Treosulfan Investigational Phase 4,Phase 2,Phase 3,Phase 1 299-75-2 9296
23
Phosphonoacetic Acid Experimental Phase 4,Not Applicable 4408-78-0 546
24 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
25 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
26 Vitamin B Complex Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
27 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
28 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
29 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
30 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
31 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
32 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
33 Antitubercular Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
34 Vitamin B9 Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
35 Folate Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
36 Cyclosporins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
38 Dermatologic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
39 Antirheumatic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
40 Folic Acid Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
41 Calcineurin Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
42 Thymoglobulin Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Antilymphocyte Serum Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
45 Antineoplastic Agents, Alkylating Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
46 Alkylating Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
47 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
48 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 894)
# Name Status NCT ID Phase Drugs
1 Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major Unknown status NCT02342145 Phase 4 Basiliximab,;cyclosporine A;Methotrexate;Mycophenolate mofetil
2 Efficacy and Safety Study of ATG for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT Unknown status NCT02677181 Phase 4 ATG;CsA;mycophenolate mofetil;Methotrexate
3 ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis Completed NCT01883180 Phase 4 ATG
4 Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD Completed NCT00574470 Phase 4 daclizumab, infliximab
5 Post-transplantation Cyclophosphamide for Haploidentical Transplant From Maternal or Collateral Donors Completed NCT02412423 Phase 4 post-transplantation cyclophosphamide
6 Study to Assess the Safety and Efficacy of Tacrolimus (Prograf Capsule/Injection) and Methotrexate (MTX) Combination Therapy for Prevention of Graft Versus Host Disease (GVHD) in Patients Who Received Peripheral Hematopoietic Stem Cell Transplantation From a Sibling Donor Completed NCT02660684 Phase 4 Prograf;Methotrexate;Cyclosporine
7 Antifugal Effect of Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) in Patients Post Allo-HSCT Completed NCT01232504 Phase 4 rhGM-CSF group;rhG-CSF+rhGM-CSF group;rhG-CSF group
8 PTCy-ATG vs ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis Recruiting NCT03689465 Phase 4 ATG;CTX;Mycophenolate Mofetil
9 Anti-thymocyte Globulins for Graft-versus-host Disease Prophylaxis Recruiting NCT01856803 Phase 4 anti thymoglobulin
10 ATG/PTCy in Haplo-PBSCT Randomized Controlled,Multi-center Recruiting NCT03608059 Phase 4 ATG/PTCy;standard ATG;standard PTCy
11 Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections Recruiting NCT02805946 Phase 4 posaconazole
12 CMV-CTL for the Treatment of CMV Infection After HSCT Recruiting NCT03004261 Phase 4 Foscarnet;Ganciclovir
13 Early Tapering of Immunosuppressive Agents to Immunomodulation to Improve Survival of AML Patients Recruiting NCT03150134 Phase 4 Cyclosporine;routine reduction of immunosuppressive drugs(cyclosporine)
14 Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major Recruiting NCT03171831 Phase 4 Busulfan;Cyclophosphamide;Fludarabine;Mycophenolate mofetil;Tacrolimus;Methotrexate;Thymoglobulin;Basiliximab
15 ALL SCTped FORUM - Pharmacogenomic Study (add-on Study) Recruiting NCT02670564 Phase 4
16 A Optimal Anti-Thymoglobuline (ATG) Dose Decrease cGVHD But Not Increase Leukemia Relapse for Haplo-HSCT Not yet recruiting NCT03190733 Phase 4 ATG
17 Study of Busulfan and FLAG Conditioning Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation Not yet recruiting NCT02784561 Phase 4 Busulfan (Zhejiang Otsuka Pharmaceutical Co. Ltd);Cytarabine(Actavis Italy S.p.A);Fludarabine (Bayer);granulocyte colony-stimulating factor (KirinKunpeng);rabbit ATG(Sanofi/Genzyme)
18 Extracorporeal Photopheresis for Acute Graft Versus Host Disease Unknown status NCT00179855 Phase 2, Phase 3
19 MSCs Combined With CD25 Monoclonal Antibody and Calcineurin Inhibitors for Treatment of Steroid-resistant aGVHD Unknown status NCT02241018 Phase 2, Phase 3 CD25 monoclonal antibody;calcineurin inhibitors
20 MSC and Cyclophosphamide for Acute Graft-Versus-Host Disease (aGVHD) Prophylaxis Unknown status NCT02270307 Phase 2, Phase 3 Cyclophosphamide
21 Randomized Study of ATG for Graft Versus Host Disease (GVHD) Prevention in Paediatric Patients Given an Unrelated Donor Stem Cell Transplantation Unknown status NCT00934557 Phase 3 ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius
22 Trial of Filgrastim Versus Placebo Following Allogeneic Bone Marrow Transplantation Unknown status NCT00207792 Phase 3 filgrastim
23 Comparison of Cy-Atg vs Flu-Atg for the Conditioning Therapy in Allo-HCT for Adult Aplastic Anemia Unknown status NCT01145976 Phase 3 Cy-ATG;Flu-ATG
24 MSCs With or Without Peripheral Blood Stem Cell for Treatment of Poor Graft Function and Delayed Platelet Engraftment Unknown status NCT02240992 Phase 2, Phase 3
25 The Effect of Folinic Acid Rescue Following MTX GVHD Prophylaxis on Regimen Related Toxicity and Transplantation Outcome Unknown status NCT02506231 Phase 2, Phase 3 Folinic acid;Placebo
26 TCR Alpha/Beta Depletion for HSCT From Haploidentical and Unrelated Donors in the Treatment of PID Unknown status NCT02327351 Phase 2, Phase 3
27 The Use of Etanercept Enbrel as Sole Treatment for Grade I Acute Graft Versus Host Disease Completed NCT00726375 Phase 3 Etanercept (Enbrel)
28 Study Comparing ABX-CBL (Monoclonal Antibody) Versus Atgam in Patients With Steroid Resistant Acute Graft Versus Host Disease Completed NCT00035880 Phase 2, Phase 3 ABX-CBL
29 Low-Dose Prednisone or Methylprednisolone in Treating Patients With Newly Diagnosed Acute Graft-versus-Host Disease Completed NCT00929695 Phase 3 prednisone;methylprednisolone
30 Efficacy and Safety of Prochymal™ Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute GVHD Completed NCT00562497 Phase 3 Prochymal
31 Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Steroid Refractory Acute Graft Versus Host Disease Completed NCT00366145 Phase 3
32 Acute Graft-Versus-Host Disease (aGvHD) Prophylaxis With ATG-Fresenius in Matched Unrelated Donor-Stem Cell Transplantation (MUD-SCT) Completed NCT00655343 Phase 3 ATG-Fresenius S
33 Methylprednisolone With or Without Daclizumab in Treating Patients With Acute Graft-Versus-Host Disease Completed NCT00053976 Phase 3 methylprednisolone;Placebo
34 A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD Completed NCT02336230 Phase 3 remestemcel-L
35 Acute Graft-versus-Host Disease Treatment (BMT CTN 0802) Completed NCT01002742 Phase 3 Mycophenolate Mofetil;Placebo
36 Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Completed NCT01231412 Phase 3 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
37 Thymoglobuline in Non-myeloablative Allogeneic Stem-cell Transplantation Completed NCT00130754 Phase 3 Thymoglobuline
38 Stem Cell Transplantation for Patients With Hematologic Malignancies Completed NCT00152139 Phase 3 Chemotherapy and antibodies
39 Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402) Completed NCT00406393 Phase 3 Tacrolimus;Methotrexate;Sirolimus
40 Tacrolimus/Methotrexate Versus Cyclosporine/Methotrexate for Prophylaxis of Graft Versus Host Disease Completed NCT01788501 Phase 2, Phase 3 Tacrolimus;Cyclosporine;Methotrexate
41 Stem Cell Transplant for Inborn Errors of Metabolism Completed NCT00176904 Phase 2, Phase 3 Busulfan, Cyclophosphamide, Antithymocyte Globulin
42 Graft-Versus-Host Disease Prevention in Treating Patients Who Are Undergoing Bone Marrow Transplantation Completed NCT00002456 Phase 3 cyclosporine;methotrexate
43 Randomized Trial Comparing Sirolimus and Tacrolimus Versus Cyclosporine and Methotrexate as Graft-versus-host Disease (GVHD) Prophylaxis After Allogeneic Stem Cell Transplantation Completed NCT00993343 Phase 3 Sirolimus/tacrolimus;cyclosporine/methotrexate
44 Comparison of Peripheral Blood Stem Cell Transplantation With Bone Marrow Transplantation for the Treatment of Serious Hematological Malignancies Completed NCT00275678 Phase 3
45 Nonmyeloablative Stem Cell Transplant in Elderly Completed NCT00382759 Phase 2, Phase 3
46 Chronic Graft-versus-host Disease (cGvHD) Prophylaxis With or Without ATG Prior to Stem Cell Transplantation (SCT) From HLA-identical Siblings in Patients With Acute Leukemia Completed NCT00678275 Phase 3 ATG FRESENIUS (Anti-Lymphocyte-Globulin);ATG FRESENIUS (Anti-Lymphocyte-Globulin)
47 Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA Completed NCT00455312 Phase 2, Phase 3 Campath 1H;Cyclophosphamide;Fludarabine;antithymocyte globulin;Methylprednisolone
48 Stem Cell Transplant for Bone Marrow Failure Syndromes Completed NCT00176878 Phase 2, Phase 3 Fludarabine monophosphate;Busulfan
49 Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD) Completed NCT01295710 Phase 3
50 Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy Completed NCT00469729 Phase 2, Phase 3 StemEx®

Search NIH Clinical Center for Acute Graft Versus Host Disease

Genetic Tests for Acute Graft Versus Host Disease

Anatomical Context for Acute Graft Versus Host Disease

MalaCards organs/tissues related to Acute Graft Versus Host Disease:

42
T Cells, Bone, Bone Marrow, Myeloid, Nk Cells, Skin, B Cells

Publications for Acute Graft Versus Host Disease

Articles related to Acute Graft Versus Host Disease:

(show top 50) (show all 1501)
# Title Authors Year
1
Recombinant Pregnancy-Specific Glycoprotein 1 Has a Protective Role in a Murine Model of Acute Graft-versus-Host Disease. ( 30253241 )
2019
2
Plasma-based protein biomarkers can predict the risk of acute graft-versus-host disease and non-relapse mortality in patients undergoing allogeneic hematopoietic stem cell transplantation. ( 30344086 )
2019
3
Histologic diagnosis and grading of esophageal acute graft-versus-host disease. ( 30607554 )
2019
4
Clinical Outcomes and Healthcare Resource Utilization for Gastrointestinal Acute Graft-versus-Host Disease after Allogeneic Transplantation for Hematologic Malignancy: A Retrospective US Administrative Claims Database Analysis. ( 30625389 )
2019
5
Diagnosis and grading of acute graft-versus-host disease in endoscopic biopsy series throughout the upper and lower intestine in patients after allogenic hematopoietic stem cell transplantation: a systematic approach. ( 30632829 )
2019
6
Mesenchymal stromal cells for acute graft-versus-host disease: response at 1 week predicts probability of survival. ( 30637732 )
2019
7
The Ex Vivo Treatment of Donor T cells with Cosalane, an HIV Therapeutic and Small Molecule Antagonist of CC-Chemokine Receptor 7, Separates Acute Graft-versus-Host Disease from Graft-versus-Leukemia Responses in Murine Hematopoietic Stem Cell Transplant Models. ( 30668984 )
2019
8
The new refined minnesota risk score for acute graft-versus-host disease predicts overall survival and non-relapse mortality after T cell-replete haploidentical stem cell transplant with post-transplant cyclophosphamide. ( 30679826 )
2019
9
G-CSF-induced macrophage polarization and mobilization may prevent acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. ( 30683906 )
2019
10
Assessment of Individual vs. Composite Endpoints of Acute GVHD in Determining Long-Term Survival after Allogeneic Transplantation. ( 30710686 )
2019
11
Limited Utility of Outpatient Surveillance Blood Cultures in Hematopoietic Cell Transplant Recipients on High-Dose Steroids for Treatment of Acute Graft-versus-Host-Disease. ( 30711778 )
2019
12
R707, a Fully Human Antibody Directed Against CC-Chemokine Receptor 7, Attenuates Xenogeneic Acute Graft-Versus-Host Disease. ( 30748092 )
2019
13
Tocilizumab as first-line therapy for steroid-refractory acute graft-versus-host-disease: analysis of a single-center experience. ( 30764681 )
2019
14
Development of pre-engraftment syndrome, but not acute graft-versus-host disease, reduces relapse rate of acute myeloid leukemia after single cord blood transplantation. ( 30771495 )
2019
15
Gastrointestinal Biopsies for Evaluation of Acute Graft-Versus-Host Disease in Allogeneic Hematopoietic Stem Cell Transplant Patients. ( 30828153 )
2019
16
Early myeloid-derived suppressor cells (HLA-DR-/lowCD33+CD16-) expanded by granulocyte colony-stimulating factor prevent acute graft-versus-host disease (GVHD) in humanized mouse and might contribute to lower GVHD in patients post allo-HSCT. ( 30885244 )
2019
17
Mesenchymal stem cells transplantation in hematological patients with acute graft-versus-host disease: characteristics and risk factors for infectious complications. ( 29380038 )
2018
18
Change of apheresis device decreased the incidence of severe acute graft-versus-host disease among patients after allogeneic stem cell transplantation with sibling donors. ( 29536557 )
2018
19
TIGIT-Fc alleviates acute graft-versus-host disease by suppressing CTL activation via promoting the generation of immunoregulatory dendritic cells. ( 29960041 )
2018
20
The glucocorticoid receptor in recipient cells keeps cytokine secretion in acute graft-versus-host disease at bay. ( 29643984 )
2018
21
Hypoalbuminaemia segregates different prognostic subgroups within the refined standard risk acute graft-versus-host disease score. ( 29345306 )
2018
22
Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft versus host disease: low incidence of lower gastrointestinal tract disease. ( 29351985 )
2018
23
Photopheresis of a less than 10-kg child with acute graft versus host disease accompanied with hyperbilirubinemia: A case report. ( 29778715 )
2018
24
The Therapeutic Effect of ICAM-1-Overexpressing Mesenchymal Stem Cells on Acute Graft-Versus-Host Disease. ( 29763906 )
2018
25
MicroRNA-155 Modulates Acute Graft-versus-Host Disease by Impacting T Cell Expansion, Migration, and Effector Function. ( 29720426 )
2018
26
Simple, Reproducible, and Efficient Clinical Grading System for Murine Models of Acute Graft-versus-Host Disease. ( 29403494 )
2018
27
Plasma vascular non-inflammatory molecule 3 is associated with gastrointestinal acute graft-versus-host disease in mice. ( 29311761 )
2018
28
Infusion of bone marrow derived multipotent mesenchymal stromal cells for the treatment of steroid-refractory acute graft-versus-host disease: a multicenter prospective study. ( 29755674 )
2018
29
Extracorporeal photopheresis in the treatment of acute graft-versus-host disease: a single-center experience. ( 29707788 )
2018
30
Extracorporeal photopheresis as second-line therapy for patients with acute graft-versus-host disease: does the number of cells treated matter? ( 29446444 )
2018
31
18F-3'-deoxy-3'-fluorothymidine (FLT) PET imaging for the prediction of acute graft-versus-host disease in mouse hematopoietic stem cell transplant models. ( 29981461 )
2018
32
Evaluation of infliximab as second-line treatment of acute graft versus host disease -validating response on day 7 and 28 as predictors of survival. ( 29391524 )
2018
33
Human Herpesvirus-6B Reactivation Is a Risk Factor for Grades II to IV Acute Graft-versus-Host Disease after Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis. ( 29684567 )
2018
34
Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM). ( 29379171 )
2018
35
Vedolizumab for treatment of steroid-refractory lower gastrointestinal acute graft-versus-host disease. ( 29371686 )
2018
36
Poor prognosis in patients with steroid refractory acute graft versus host disease treated with etanercept: a multi-centre analysis. ( 29795434 )
2018
37
Acute Graft-versus-Host Disease. ( 29419277 )
2018
38
Intestinal Microbiota at Engraftment Influence Acute Graft-Versus-Host Disease <i>via</i> the Treg/Th17 Balance in Allo-HSCT Recipients. ( 29740427 )
2018
39
Tocilizumab for the treatment of severe steroid-refractory acute graft-versus-host disease of the lower gastrointestinal tract. ( 29795429 )
2018
40
Mycophenolate mofetil administered every 8 hours in combination with tacrolimus is efficacious in the prophylaxis of acute graft versus host disease in childhood, adolescent, and young adult allogeneic stem cell transplantation recipients. ( 29667720 )
2018
41
Regulatory I^I' T cells induced by G-CSF participate in acute graft-versus-host disease regulation in G-CSF-mobilized allogeneic peripheral blood stem cell transplantation. ( 29801459 )
2018
42
Association analysis between SUFU polymorphism rs17114808 and acute graft versus host disease after hematopoietic stem cell transplantation. ( 29330404 )
2018
43
Pharmacokinetic and Pharmacodynamic Markers of Mycophenolic Acid Associated with Effective Prophylaxis for Acute Graft-Versus-Host Disease and Neutrophil Engraftment in Cord Blood Transplant Patients. ( 29427741 )
2018
44
Acute Graft-versus-Host Disease. ( 29414273 )
2018
45
Prediction of absolute risk of acute graft-versus-host disease following hematopoietic cell transplantation. ( 29346409 )
2018
46
CXCR3 blockade combined with cyclosporine A alleviates acute graft-versus-host disease by inhibiting alloreactive donor T cell responses in a murine model. ( 29288898 )
2018
47
MicroRNA in T-Cell Development and T-Cell Mediated Acute Graft-Versus-Host Disease. ( 29867969 )
2018
48
Extracorporeal photopheresis is a valuable treatment option in steroid-refractory or steroid-dependent acute graft versus host disease-experience with three different approaches. ( 29907805 )
2018
49
I+<sub>1</sub>-Antitrypsin Infusion for treatment of Steroid Resistant Acute Graft-versus-Host Disease. ( 29437593 )
2018
50
Peritransplantation Ruxolitinib Prevents Acute Graft-versus-Host Disease in Patients with Myelofibrosis Undergoing Allogenic Stem Cell Transplantation. ( 29800615 )
2018

Variations for Acute Graft Versus Host Disease

Expression for Acute Graft Versus Host Disease

Search GEO for disease gene expression data for Acute Graft Versus Host Disease.

Pathways for Acute Graft Versus Host Disease

Pathways related to Acute Graft Versus Host Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 63)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.98 ARHGAP45 FASLG IFNG IL10 IL18 IL2
2
Show member pathways
13.82 FASLG IL10 IL18 IL2 IL2RA IL4
3
Show member pathways
13.67 FASLG IFNG IL10 IL18 IL2 IL2RA
4
Show member pathways
13.49 IFNG IL10 IL18 IL2 IL2RA IL4
5
Show member pathways
13.41 FASLG IL10 IL18 IL2 IL2RA IL4
6
Show member pathways
13.35 FASLG IFNG IL10 IL18 IL2 IL2RA
7
Show member pathways
13.29 FASLG IL10 IL18 IL2 IL2RA IL4
8
Show member pathways
13.22 FASLG IFNG IL10 IL18 IL2 NOD2
9
Show member pathways
12.96 FASLG IL2 IL2RA IL4 TNF
10
Show member pathways
12.87 FASLG GZMB IFNG IL10 IL18 IL2
11 12.83 FASLG IFNG IL2 IL2RA IL4
12
Show member pathways
12.67 IFNG IL10 IL18 IL2 IL2RA IL4
13
Show member pathways
12.62 IFNG IL10 IL18 IL2 TNF
14
Show member pathways
12.62 FASLG IFNG IL18 IL2 IL2RA IL4
15
Show member pathways
12.58 FASLG GZMB IFNG IL2 IL4 TNF
16
Show member pathways
12.57 IFNG IL10 IL18 IL2 IL2RA IL4
17
Show member pathways
12.48 IFNG IL10 IL2 IL4 TNF
18
Show member pathways
12.44 IFNG IL10 IL2 IL2RA IL4
19
Show member pathways
12.34 IFNG IL2 IL4 TNF
20 12.32 FASLG GZMB IFNG IL10 IL2 IL2RA
21 12.31 IFNG IL10 IL18 NOD2 TNF
22
Show member pathways
12.3 IFNG IL10 IL18 IL2 IL2RA IL4
23
Show member pathways
12.28 IFNG IL10 IL4 TNF
24
Show member pathways
12.21 FASLG IFNG IL4 TNF
25
Show member pathways
12.14 IFNG IL10 IL18 IL2 IL2RA IL4
26
Show member pathways
12.14 IFNG IL10 IL18 IL2 TNF
27 12.07 FASLG IL10 IL18 IL4 TNF
28 12.07 IFNG IL10 IL2 IL2RA IL4 TNF
29 12.06 IFNG IL2 IL4 TNF
30
Show member pathways
12.03 IFNG IL2 IL2RA
31
Show member pathways
12 IFNG IL4 TNF
32 11.93 IFNG IL10 IL2 IL2RA
33 11.88 IL2RA IL4 TNF
34 11.88 IFNG IL10 TNF
35 11.85 IFNG IL18 TNF
36
Show member pathways
11.85 FASLG GZMB IFNG IL18 IL2 IL2RA
37 11.83 IFNG IL18 MYH9
38 11.83 IFNG IL10 IL2 TNF
39 11.8 IFNG IL2 IL4
40
Show member pathways
11.79 FASLG IL2 IL2RA IL4
41
Show member pathways
11.76 FASLG IFNG IL2 IL2RA IL4 TNF
42 11.7 IFNG IL10 IL18 IL2 IL4 TNF
43
Show member pathways
11.68 IFNG IL2 TNF
44 11.65 FASLG IFNG IL2 TNF
45 11.63 IL10 IL18 IL4 TNF
46 11.62 IFNG IL10 IL18 TNF
47 11.56 IFNG IL2 TNF
48 11.56 IFNG IL18 TNF
49 11.52 FASLG IFNG TNF
50 11.48 FASLG IFNG IL10 IL18 TNF

GO Terms for Acute Graft Versus Host Disease

Cellular components related to Acute Graft Versus Host Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.7 FASLG IFNG IL10 IL18 IL2 IL4
2 external side of plasma membrane GO:0009897 9.56 FASLG IL2RA TNF TNFRSF4
3 cell surface GO:0009986 9.35 FASLG IL2RA NOD2 TNF TNFRSF4
4 extracellular region GO:0005576 9.23 ARHGAP45 FASLG IFNG IL10 IL18 IL2

Biological processes related to Acute Graft Versus Host Disease according to GeneCards Suite gene sharing:

(show all 43)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.98 IFNG IL18 IL4 TNF
2 inflammatory response GO:0006954 9.98 IL10 IL18 TNF TNFRSF4
3 MAPK cascade GO:0000165 9.89 IL18 IL2 IL2RA TNF
4 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.86 IL18 NOD2 TNF
5 negative regulation of inflammatory response GO:0050728 9.84 IL10 IL2 IL2RA
6 positive regulation of inflammatory response GO:0050729 9.82 IL18 IL2 TNF
7 cellular response to organic cyclic compound GO:0071407 9.81 IL18 NOD2 TNF
8 tumor necrosis factor-mediated signaling pathway GO:0033209 9.81 FASLG TNF TNFRSF4
9 positive regulation of T cell proliferation GO:0042102 9.76 IL2 IL2RA IL4
10 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.75 IL18 NOD2 TNF
11 extrinsic apoptotic signaling pathway GO:0097191 9.73 FASLG IFNG TNF
12 positive regulation of interferon-gamma production GO:0032729 9.72 IL18 IL2 TNF
13 regulation of signaling receptor activity GO:0010469 9.7 FASLG IFNG IL10 IL18 IL2 IL4
14 natural killer cell mediated cytotoxicity GO:0042267 9.69 GZMB IL18
15 positive regulation of osteoclast differentiation GO:0045672 9.68 IFNG TNF
16 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.68 IFNG TNF
17 negative regulation of growth of symbiont in host GO:0044130 9.67 IL10 TNF
18 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.67 IL10 TNF
19 positive regulation of B cell proliferation GO:0030890 9.67 IL2 IL4 TNFRSF4
20 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.67 IFNG IL18 IL2 IL4
21 positive regulation of immunoglobulin secretion GO:0051024 9.66 IL2 TNFRSF4
22 interleukin-2-mediated signaling pathway GO:0038110 9.66 IL2 IL2RA
23 positive regulation of isotype switching to IgG isotypes GO:0048304 9.65 IL2 IL4
24 endothelial cell apoptotic process GO:0072577 9.64 IL10 TNF
25 positive regulation of MHC class II biosynthetic process GO:0045348 9.63 IL10 IL4
26 positive regulation of activated T cell proliferation GO:0042104 9.63 IL18 IL2 IL2RA
27 necroptotic signaling pathway GO:0097527 9.62 FASLG TNF
28 negative regulation of cytokine secretion involved in immune response GO:0002740 9.62 IL10 TNF
29 negative regulation of lymphocyte proliferation GO:0050672 9.61 IL2 IL2RA
30 positive regulation of neuroinflammatory response GO:0150078 9.61 IL18 TNF
31 positive regulation of T cell differentiation GO:0045582 9.61 IL2 IL2RA IL4
32 positive regulation of tissue remodeling GO:0034105 9.6 IL18 IL2
33 regulation of regulatory T cell differentiation GO:0045589 9.58 IFNG IL2 IL2RA
34 regulation of isotype switching GO:0045191 9.57 IL10 IL4
35 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.54 IFNG TNF
36 receptor biosynthetic process GO:0032800 9.52 IL10 TNF
37 regulation of T cell homeostatic proliferation GO:0046013 9.51 IL2 IL2RA
38 positive regulation of interleukin-17 production GO:0032740 9.5 IL18 IL2 NOD2
39 cytokine-mediated signaling pathway GO:0019221 9.5 FASLG IL10 IL18 IL2 IL2RA IL4
40 positive regulation of vitamin D biosynthetic process GO:0060557 9.48 IFNG TNF
41 type 2 immune response GO:0042092 9.43 IL10 IL18 IL4
42 immune response GO:0006955 9.28 FASLG IFNG IL10 IL18 IL2 IL2RA
43 positive regulation of transcription by RNA polymerase II GO:0045944 10.13 IL10 IL18 IL2 IL4 NOD2 TNF

Molecular functions related to Acute Graft Versus Host Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.77 ARHGAP45 FASLG GZMB IFNG IL10 IL18
2 cytokine activity GO:0005125 9.17 FASLG IFNG IL10 IL18 IL2 IL4

Sources for Acute Graft Versus Host Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....